-+ 0.00%
-+ 0.00%
-+ 0.00%

China's CDE Accepts Hangzhou Jiuyuan's JY54-2 Clinical Trial Application

PUBT·11/06/2026 09:33:36
Listen to the news
China's CDE Accepts Hangzhou Jiuyuan's JY54-2 Clinical Trial Application
  • China's Center for Drug Evaluation accepted Hangzhou Jiuyuan Gene Engineering's investigational new drug application for JY54-2 Injection.
  • The application covers type 2 diabetes and weight management in obese or overweight patients. A Phase I trial is planned.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hangzhou Jiuyuan Gene Engineering Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261106-12403853), on November 06, 2026, and is solely responsible for the information contained therein.